DTC

DTC expected to propel Afrezza awareness, not necessarily sales

DTC expected to propel Afrezza awareness, not necessarily sales

By

Havas Health developed the inhaled insulin's advertising campaign, which is slated to kick off later this summer.

Five things for pharma marketers to know: Thursday, April 16

Five things for pharma marketers to know: Thursday, April 16

By

FDA approves Amgen heart failure drug; Pfizer halts breast-cancer drug trial over positive results; 30% of study participants asked docs about drug after seeing or reading an ad

Patients do not feel connected to pharma

Patients do not feel connected to pharma

By

Wego Health says fixing this problem requires incorporating patient perspectives before and after a product launch.

How to Make DTC Ad 'Warnings' More Effective

How to Make DTC Ad 'Warnings' More Effective

A more general warning encourages consumers to engage in a personal discussion with their doctor about a drug, and it promotes engagement with longer-format printed or digitally-delivered information.

Pharma DTC spending jumps almost 21% in 2014

Pharma DTC spending jumps almost 21% in 2014

By

Nielsen data shows pharma spent $4.5 billion on DTC ads last year.

FDA updates DTC ad policy on risk information

FDA updates DTC ad policy on risk information

By

FDA posted a revised draft guidance document on its brief summary and adequate directions for use concerning risk information in DTC print ads to reflect "recent social science research."

FDA to study impact of shorter DTC risk list

FDA to study impact of shorter DTC risk list

By

The FDA is looking into whether abbreviated risk information is a good idea for DTC.

Patients to influence voice of Lemtrada consumer campaign

Patients to influence voice of Lemtrada consumer campaign

By

Patient advocates lobbied the FDA to approve the MS drug and Sanofi subsidiary Genzyme says their voice will be part of the consumer outreach when DTC rolls out next year.

Five things for pharma marketers to know: Wednesday, November 19

Five things for pharma marketers to know: Wednesday, November 19

By

Sanofi vets Takeda, devicemaker CEO candidates; Shaq returns for IcyHot; Royalty Pharma buys royalties on Vertex's Kalydeco.

Field Notes: WPP's Stream Tackles Health Issues

Field Notes: WPP's Stream Tackles Health Issues

By

Stream Health, WPP's "unconference" which took place in Florida earlier this week, provided a diverse and large amount of content in a short amount of time.

Nurses undeterred by internet bans at work: study

Nurses undeterred by internet bans at work: study

By

Healthcare workers seek out health-related information on their own time, and through internet connections other than ones offered by their employers.

Everyday Health adds payer expert

The media company has added managed-markets expertise to its roster, bringing on the former head of IMS Health's global payer/provider division.

CVS changes name

Parent company CVS Caremark is changing its name to better reflect "its broader health care commitment."

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, August 20

By

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma company to pair with the Crohn's and Colitis Foundation of America.

GSK relaunches COPD.com

GSK relaunches COPD.com

By

The refresh launched soon after the company encouraged investors to take a long view of GSK as the firm posted weak respiratory numbers.

Doctors do not care about your Fitbit

Tech site Venturebeat, citing anonymous sources, says doctors are too overwhelmed and weary to evaluate how many steps you took this weekend.

As Pharma Slowly Opens Up, Patients Are Engaging Themselves

As Pharma Slowly Opens Up, Patients Are Engaging Themselves

Influential patients are reaching critical mass. What can't they do?

Healthy-habit trackers have short-lived appeal

A study indicates consumers stop using them at the six-month mark.

Belviq scripts jump on DTC, rep push

Belviq scripts jump on DTC, rep push

By

Arena's recent quarter shows weight-loss drug Belviq is on the rise. It follows a DTC push and the recent addition of reps by co-marketer Eisai.

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.

Miss Idaho shows off diabetes pump

NPR reports that the move has made Sierra Sandison a type 1 diabetes hero and that users have given the Facebook photo over 4,000 "likes."

Digital sage Richman returns to healthcare

He started the Dose of Digital blog in 2008, then left healthcare. Now, after more than two years away, Jonathan Richman says he's back in the business.

"Likes" put Zarbee's in FDA crosshairs

"Likes" put Zarbee's in FDA crosshairs

By

The FDA says the OTC remedy maker's online behavior—including Liking customer Facebook posts—has put the company's drugs in unapproved drug territory.

OPDP slaps Gilead with Untitled Letter

OPDP slaps Gilead with Untitled Letter

By

The drugmaker received a notice from the advertising watchdog over promotion of hep. B treatment Viread in a sponsored link on Google AdWords.

Key to successful digital outreach: think small

Key to successful digital outreach: think small

By

Patients want to do more with mobile and see doctors less. Two studies outline the types of digital interventions patients are interested in.

Merck consumer guide gets 21st-century treatment

Merck consumer guide gets 21st-century treatment

By

The consumer-facing edition of The Merck Manual Go-To Home Guide for Symptoms is being released as a mobile app.

Researchers give FDA social media advice

Researchers give FDA social media advice

By

Researchers from Boston Children's Hospital, Harvard Medical School and Brigham and Women's Hospital are offering a bit of internet advice for the Food and Drug Administration: do more.

Facebook's clinical trial

The networking site's emotion experiment rankles some in the science and political communities.

Why the US Didn't Do Well at Lions Health

Why the US Didn't Do Well at Lions Health

A US Pharma juror's—and silver Lions Health winner's—opinion on why the Americans didn't fare well in Cannes, and tips for improvement

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.